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Abstract
Background: Intraplantar administration of complete Freund's adjuvant (CFA) and formalin are two noxious stimuli
commonly used to produce sustained pain-related behaviors in rodents for research on neurobiology and treatment
of pain. One clinically relevant manifestation of pain is depression of behavior and mood. This study compared effects
of intraplantar CFA and formalin on depression of positively reinforced operant behavior in an assay of intracranial
self-stimulation (ICSS) in rats. Effects of CFA and formalin on other physiological and behavioral measures, and opioid
effects on formalin-induced depression of ICSS, were also examined.
Results: There were four main findings. First, consistent with previous studies, both CFA and formalin produced similar
paw swelling and mechanical hypersensitivity. Second, CFA produced weak and transient depression of ICSS, whereas
formalin produced a more robust and sustained depression of ICSS that lasted at least 14 days. Third, formalin-induced
depression of ICSS was reversed by morphine doses that did not significantly alter ICSS in saline-treated rats, suggesting
that formalin effects on ICSS can be interpreted as an example of pain-related and analgesic-reversible depression of
behavior. Finally, formalin-induced depression of ICSS was not associated with changes in central biomarkers for
activation of endogenous kappa opioid systems, which have been implicated in depressive-like states in rodents, nor
was it blocked by the kappa antagonist norbinaltorphimine.
Conclusions: These results suggest differential efficacy of sustained pain stimuli to depress brain reward function in rats
as assessed with ICSS. Formalin-induced depression of ICSS does not appear to engage brain kappa opioid systems.
Keywords: Complete Freund’s adjuvant, Formalin, Pain/analgesics, Depression, Intracranial self-stimulation, Kappa opioid
Introduction
Preclinical procedures to evaluate pain and analgesia in
laboratory animals play a key role in research on both
neurobiology of pain and analgesic drug development
[1-3]. Two common chemical challenges for induction
of sustained pain states in rodents are intraplantar
administration of Complete Freund’s Adjuvant (CFA)
and formalin. CFA is a heat-killed bacterial suspension
that elicits an immune response at the site of its injection.
For example, CFA administration in the hindpaw of rats
or mice produces paw edema [4-6] and increased local
concentrations of inflammatory cytokines and trophic
factors [7]. These and other inflammatory mediators
contribute to peripheral and central sensitization of
nociceptive neural pathways [8-10], and this neural
hypersensitivity correlates with a sustained behavioral
hypersensitivity of withdrawal responses to mechanical or
thermal stimuli [5,11,12]. These hypersensitive withdrawal
responses often serve as a behavioral indicator of “pain”.
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hyde, a cell toxin that cross links proteins to disrupt
dynamic protein interactions critical to cell viability.
Formalin functions as an acute irritant, and when
administered into the hindpaw of rodents, it elicits
transient behaviors such as flinching and paw-licking
[13-15,12]. However, formalin also elicits a sustained
inflammatory response characterized by edema and local
release of inflammatory mediators [12]. Moreover, formalin
also damages or kills cells, including primary nociceptors
and other sensory neurons, and as a result, formalin-induced
changes in behavior also include a neuropathic component.
For example, formalin injection into the hindpaw of rodents
has been shown to produce general necrosis at the site of
injection, increased expression of the neuropathy-related
transduction factor ATF-3 in dorsal root ganglion cell
bodies, and increased spinal microglial activation to an
extent similar to that produced by other neuropathy
models [16,12,17]. Consistent with this evidence for
long-lasting tissue injury, intraplantar formalin also
produces hypersensitivity to mechanical and thermal
stimuli, and as with CFA, this hypersensitivity is sustained
for days or weeks and often serves as a behavioral indicator
of pain [15,18].
We have categorized behaviors such as hypersensitive
paw withdrawal reflexes as “pain-stimulated behaviors,”
which are defined as behaviors that increase in rate,
frequency or intensity after delivery of a pain stimulus
[1,19]. However, pain states can also depress other
behaviors, and treatment of pain-related behavioral
depression is a common goal of human and veterinary
medicine [20,21]. Research on pain-related depression of
behavior can be accomplished with procedures that
measure “pain-depressed behaviors,” which can be defined
as behaviors that decrease in rate, frequency or intensity
after a pain stimulus [1,19]. For example, intracranial
self-stimulation is a procedure in which subjects perform
an operant behavior (e.g. press a lever) to receive pulses of
electrical stimulation that activate the mesolimbic
dopamine system, and ICSS has been used to examine
effects of various manipulations on brain reward function
[22-24]. Previous studies have reported relatively transient
depression of ICSS by acute noxious stimuli including
intraperitoneal (IP) injection of dilute acid or paw incision
[25-27]. The goal of the present study was to compare
effects of intraplantar CFA and formalin as more sustained
pain stimuli on ICSS in rats. We hypothesized that both
stimuli would produce sustained depression of ICSS
similar to their shared ability to produce sustained
thermal and mechanical hypersensitivity. Pain-related
depression of ICSS was evaluated for its sensitivity to
reversal by the mu opioid analgesic morphine. In addition,
pain-related depression of ICSS was evaluated for its
relationship to central biomarkers of the endogenous
kappa opioid system and its sensitivity to the kappa
antagonist norbinaltorphimine (norBNI), because some
other stressors depress behavior by activating central
kappa systems [28,29].
Methods
Subjects
Studies were conducted in male Sprague-Dawley rats
(Harlan, Frederick MD) with initial weights of 285 to
350 g. Rats were individually housed and maintained on
a 12-h light/dark cycle with lights on from 6:00 AM to
6:00 PM. Food and water were continuously available in
the home cage. Animal-use protocols were approved by
the Virginia Commonwealth University Institutional
Animal Care and Use Committee and complied with
the National Research Council (2011) Guide for the Care
and Use of Laboratory Animals.
Noxious stimuli and Drugs
CFA was obtained from Sigma Aldrich (St. Louis, MO;
Catalog #F5881). Formalin was obtained from Fisher
Scientific (Waltham, MA; Catalog #305-510) and diluted
in saline to final concentrations as described below. Rats
were lightly restrained in a soft cloth for 100 ul bilateral
injections administered into the plantar aspect of the
left and right hind paws using a 27 gauge needle.
Morphine sulfate (National Institute on Drug Abuse Drug
Supply Program; Bethesda, MD) and norbinaltorphimine
2HCl (synthesized by K. Cheng and K. Rice) were
dissolved in saline for s.c. injection, and doses are expressed
as the salt.
Intracranial self-stimulation
Training
Sixty-eight rats were implanted with electrodes targeting
the medial forebrain bundle and trained to respond for
brain stimulation using experimental chambers and
procedures identical to those described previously [30].
Briefly, a white house light was illuminated during
behavioral sessions, and responding under a fixed-ratio 1
schedule produced a 0.5-s train of 0.1-ms square-wave
cathodal pulses (0.1-ms pulse duration) together with
0.5 s illumination of stimulus lights over the response
lever. The terminal schedule consisted of sequential
10-min components. During each component, one of a
descending series of 10 current frequencies was presented
(2.20-1.75 log Hz in 0.05-log increments), with a 60-s trial
at each frequency. Each frequency trial consisted of a 10-s
timeout, during which five noncontingent stimulations
were delivered at the frequency available during that
trial, followed by a 50-s “response” period, during which
responding produced electrical stimulation. Training
continued with presentation of three sequential com-
ponents per day until rats reliably responded for the
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three consecutive days.
Experiment 1: Comparison of CFA and formalin
Once training was complete, baseline pre-injection ICSS
was assessed for three consecutive days. Next, rats
received bilateral intraplantar injections of CFA, 5%
formalin, or saline. On the day of injection (Day 0),
3 “baseline” ICSS components were conducted before
injection, and pairs of ICSS test components were
conducted 1, 3, and 10 hr after injection. In addition,
in the formalin and associated saline control groups,
ICSS was also evaluated during five consecutive test
components from 0-50 mins after injection, a time when
formalin has been reported to elicit unconditioned
flinching responses (“Phase I” and “Phase II” of the
formalin response; [13-15,12]. On Days 1-7 after injection,
ICSS was evaluated during three-component test sessions
beginning at approximately 3 PM each day. Additionally,
on days 1, 3 and 7, manipulations of the height of the
ICSS response lever were introduced in a subset of 6 rats
from each group as a potential “use-dependent” measure
of injection effects on ICSS responding. Specifically, after
testing with the standard low lever height (1.5 in above
the floor), ICSS was redetermined with a medium lever
height (2.75 in), and a high lever height (4.5 in), and these
lever heights required increasingly vertical postures by the
rat and increased weight bearing by the injected rear paws.
Lever heights were presented in ascending order, with a
30-min time out between testing at each height.
ICSS was significantly depressed in the formalin-treated
group on Day 7 after injection. To assess the sensitivity of
formalin-induced depression of ICSS to treatment with an
analgesic drug, an additional test with the mu opioid
agonist morphine was conducted on Day 8 in the formalin
and associated control groups. Following determination of
baseline ICSS performance during three ICSS components
as described above, cumulative doses of morphine
(0.32-3.2 mg/kg s.c.) were administered at 60 min intervals,
such that each dose increased the total, cumulative dose by
0.5 log units. Thirty minutes after each dose of morphine,
a pair of ICSS test components was conducted.
Paw edema, body weight and mechanical sensitivity
were measured in conjunction with ICSS in this group.
To assess edema, dorsal-ventral thickness of the left
hind paw was measured with electronic digital calipers
(Traceable Calipers, Friendswood, TX) to the nearest
0.01 mm. Body weights were assessed using an electric
scale (resolution 0.1 g). The von Frey filament test was used
to measure sensitivity to a punctate pressure stimulus. Rats
were placed on an elevated mesh galvanized steel platform
in individual chambers with a hinged lid and allowed
to acclimate for at least 20 min. Subsequently, von Frey
filaments (0.4 - 15 g in approximate 0.25 log increments;
North Coast Medical, Morgan Hill, CA) were applied
to the plantar aspect of the left hind paw using the
“up-down” method to determine log median withdrawal
threshold [31]. Paw thickness and body weight were
assessed for each of three days before intraplantar injec-
tions and daily on Days 1-7 after intraplantar injection.
Mechanical sensitivity was assessed for three days before
injection, 6 hr after injection on Day 0, and on Days 3 and
7 after injection. All measurements were determined after
daily ICSS sessions.
Experiment 2: Dose-dependence and persistence of
formalin effects
Twenty-four rats were trained in the ICSS procedure
and divided into four separate groups of six each that
received 0.5% bilateral formalin, 5% unilateral formalin in
one paw + saline in the opposite paw, 5% bilateral formalin,
or bilateral saline control. ICSS was evaluated daily for
three days before injection and for 14 days after injection.
Experiment 3: Effects of norBNI on formalin-depressed ICSS
Twelve rats were trained in the ICSS procedure and
divided into two groups of six rats that received bilateral
5% formalin or bilateral saline control. ICSS was evaluated
for three days before injection and for 14 days after injec-
tion. NorBNI (32 mg/kg s.c.) was administered immediately
after ICSS testing on Day 7. Previous studies found that this
dose of norBNI was sufficient to block depression of ICSS
produced by the kappa agonist U69,593 for at least three
days [30].
Data analysis
The primary dependent measure for ICSS experiments
was the total number of stimulations delivered across all 10
frequency trials of each component. The first ICSS compo-
nent each day was considered to be a warm-up component,
and data were discarded. Baseline ICSS in each subject was
determined by averaging the number of stimulations per
component during the second and third components across
the three pre-injection baseline days (6 components total).
Data collected after intraplantar injections for each
subject were then normalized to these baselines using
the equation % Baseline Stimulations per Component=
(Stimulations per Test Component /Baseline) × 100.
An additional dependent measure was the reinforcement
rate in stimulations/trial during each of the 10 frequency
trials. To normalize these data, raw reinforcement rates
from each trial in each rat were converted to percentage of
maximum control rate (%MCR) for that rat, with the
maximum control rate defined as the mean of the
maximal rates observed during any frequency trial of
the second and third baseline components across the
three pre-injection baseline days. Thus, %MCR values
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a frequency trial ÷ maximum control rate)×100.
Data for ICSS, paw thickness, body weight and
mechanical sensitivity were averaged across rats in each
experimental condition and compared by two- or three-way
ANOVA as appropriate. For all analyses, a significant
ANOVA was followed by the Holm-Sidak post-hoc test,
and the criterion for significance was set a priori at p<0 .05 .
Quantitative real-time reverse transcriptase polymerase
chain reaction
Twenty-four rats were used for qRT-PCR studies to assess
CFA and formalin effects on endogenous prodynorphin
(PDYN) and kappa opioid receptor (KOR) mRNA in
selected brain areas as described previously [30]. Rats
were treated with 100 ul bilateral intraplantar injections of
saline, CFA, 0.5% formalin or 5% formalin (N=6 per
treatment), then euthanized seven days later by rapid
decapitation. Brains were immediately extracted, rapidly
frozen in -80°C isopentane, and stored at -80°C until
analysis. Briefly, brains were sliced on a cryostat, and
bilateral tissue punches were collected from ventral
tegmental area, nucleus accumbens core and shell,
caudate/putamen, and prefrontal cortex. PDYN and
KOR mRNA values were divided by the average values of
the two internal controls (β-actin and Calnexin). Values
are reported as percent saline controls calculated as
(normalized saline and experimental means/normalized
saline group mean for the corresponding time point) ×
100. Data for PDYN and KOR mRNA were analyzed using
two-way ANOVA with treatment and brain areas as the
two factors.
Results
Figure 1 shows effects of intraplantar saline, CFA or
formalin on paw thickness, body weight and mechanical
sensitivity. All statistical results for this and other figures
are presented in the figure legends and in Additional file 1.
Intraplantar saline had no effect on paw thickness; however,
both CFA and formalin produced significant and sustained
increases in paw thickness (e.g. edema) within 24 hours,
and these effects persisted for 7 days (Figure 1A,B). Body
weight increased significantly in the saline-control group
for the CFA rats (Figure 1C), but this increase was small,
and weight gain was not significant in the control group for
the formalin rats (Figure 1D). Administration of CFA, but
not formalin, reduced body weight within 24 hours,
and body weight in CFA rats remained below baseline for
7 days (Figure 1C,D). Saline had no effect on mechanical
sensitivity; however, both CFA and formalin produced
significant and sustained decreases in mechanical
thresholds for eliciting paw withdrawal within 6 hours,
and this hypersensitivity persisted for 7 days (Figure 1E,F).
Figure 2 shows effects of intraplantar saline, CFA or
formalin on intracranial self-stimulation (ICSS). Prior
to intraplantar injections, the mean ± SEM baseline
number of stimulation per component across all stimulation
frequencies was 264 ±13, and the mean ± SEM maximum
control rate (MCR) at any one frequency trial was 58.9±2
stimulations per trial. Intraplantar saline treatment did not
alter ICSS at any time. CFA produced weak and transient
depression of ICSS. Specifically, at 1 and 3 hr after injection,
ICSS in the CFA-treated rats was significantly lower
than ICSS in the saline-treated controls (Figure 2A);
however, ICSS in CFA- and saline-treated rats did not
differ after 3 hr, and within the CFA group, ICSS after CFA
treatment never differed significantly from baseline ICSS
before CFA. Figure 2C shows full frequency-rate ICSS
curves at selected times in the CFA-treated group. At base-
line before CFA administration, electrical brain stimulation
maintained a frequency-dependent increase in ICSS. In this
analysis, ICSS was significantly decreased at several brain-
stimulation frequencies after 1 hr but not after 7 days. In
contrast to CFA, formalin produced a more robust and sus-
tained depression of ICSS (Figure 2B). Relative to the saline
control group, formalin significantly reduced ICSS during
the first 24 hr after treatment and again during Days 5-7
after treatment. Relative to the pre-formalin baseline
within the formalin group, formalin significantly depressed
ICSS during the first 10 hr and again on Day 7 after
treatment. Figure 2D shows full frequency-rate curves
at selected times in the formalin treated group. Formalin
significantly depressed ICSS at multiple frequencies both
1 hr and 7 days after treatment.
Additional file 2: Figure S1 shows formalin effects on
ICSS during the first 50 min after formalin administration.
Formalin decreased ICSS throughout the first 50 min
of testing, although the magnitude of this decrease
was greatest from 20-50 min after treatment.
Additional file 3: Figure S2 shows CFA and formalin ef-
fects on ICSS at different lever heights in a subset of six rats
from each group on Days 1, 3 and 7 after intraplantar treat-
ment. In general, ICSS decreased as lever height increased,
and this effect was largest on Day 1. CFA failed to signifi-
cantly alter ICSS at any lever height on any day, whereas
formalin depressed ICSS across all lever heights and days.
Figure 3 shows effects of morphine on ICSS 8 days after
treatment with intraplantar saline or formalin. In the saline-
treated rats, cumulative dosing with 0.32-3.2 mg/kg
morphine produced no significant effect on ICSS.
Conversely, in the formalin-treated rats, baseline ICSS was
depressed before morphine administration, and morphine
produced a dose-dependent reversal of formalin-induced
depression of ICSS. The lowest dose of 0.32 mg/kg
morphine was sufficient to restore ICSS back to approxi-
mately baseline levels, and higher morphine doses produced
a further facilitation of ICSS.
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period after treatment with (a) bilateral saline, (b)
bilateral 0.5% formalin, (c) unilateral 5% formalin in
one paw + unilateral saline in the other paw, and (d)
bilateral 5% formalin. Prior to intraplantar injections, the
mean ± SEM baseline number of stimulations per compo-
nent across all stimulation frequencies was 274±14, and
the mean ± SEM MCR at any one frequency was 55.9± 3.
As in the first experiment, bilateral 5% formalin depressed
ICSS relative to bilateral saline treatment, and in this
second experiment, the formalin effect persisted for
14 days. Unilateral 5% formalin decreased ICSS relative to
saline controls only on Days 1 and 6, and bilateral 0.5%
formalin did not alter ICSS relative to the saline controls.
Figure 5 shows data to address the role of kappa
opioid systems in mediating effects of CFA and formalin
on ICSS. Neither CFA nor formalin significantly altered
expression of PDYN or KOR mRNA in any brain
Figure 1 Effects of complete Freund’s adjuvant (CFA), formalin, or respective controls on paw width, body weight and mechanical
sensitivity. The abscissae for all panels is hours or days following bilateral 100 ul injection of CFA (gray bars, Panels A, C, E), formalin (filled bars,
Panels B, D, F), or respective saline controls (open bars, all panels). Bars above “BL” show baseline data before injection. Ordinates (Panels A, B):
paw width in mm. Ordinates (Panels C, D): body weight in grams. Ordinates (Panels E, F): paw withdrawal threshold from von Frey filaments in
grams (log scale). Dollar signs ($) indicate a significant within-group difference from the respective baseline, and asterisks (*) indicate a significant
between-group difference at a given time point, as determined by a significant two-way Repeated Measures ANOVA followed by the Holm-Sidak
post hoc test (p<0.05). All points show mean ± SEM from 8 rats. See Additional file 1 for detailed statistical results.
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and B: Abscissae show hours or days following bilateral 100 ul injection of CFA (gray bars, Panel A), formalin (filled bars, Panel B), or respective
saline controls (open bars, both panels). Ordinates show ICSS rate expressed as total stimulations per component relative to pre-injection baseline.
Dollar signs ($) indicate a significant within-group difference from the respective baseline, and asterisks (*) indicate a significant between-group
difference at that time point. Panels C and D show full frequency-rate ICSS curves for selected time points from A and B. Abscissae show frequency of
electrical brain stimulation (Log Hz). Ordinates show ICSS rate expressed as percent maximum control rate (%MCR). Filled points indicate statistical
significance of treatment effects relative to the pre-injection baseline. All statistical analyses were performed using two-way Repeated Measures ANOVA
followed by the Holm-Sidak post hoc test (p<0.05). All points show mean ± SEM from 8 rats. See Additional file 1 for detailed statistical results.
Figure 3 Effects of the mu opioid agonist morphine (0.32-3.2 mg/kg) on ICSS eight days after bilateral intraplantar saline or 5%
formalin. Panels A and B: Abscissae show frequency of electrical brain stimulation (Log Hz) in rats that received intraplantar saline (A) or formalin
(B). Ordinates show ICSS rate expressed as percent maximum control rate (%MCR). “BL” shows the baseline frequency-rate curve determined
before intraplantar treatment, “0.0” shows the frequency-rate curve determined on Day 8 after intraplantar treatment but before morphine treatment.
Filled points in panel B show significant morphine effects relative to “0.0.” Panel C: The abscissa shows morphine dose in mg/kg in rats that received
intraplantar saline (open bars) or formalin (filled bars). The ordinate shows ICSS rate expressed as total stimulations per component relative to baseline.
Dollar signs ($) indicate a significant within-group difference from “0.0”, and asterisks (*) indicate a significant between-group difference at a given
morphine dose. All statistical analyses were performed using a two-way Repeated Measures ANOVA followed by the Holm-Sidak post-hoc test
(p<0.05). All data show mean ± SEM from 8 rats per treatment. See Additional file 1 for detailed statistical results.
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(Figure 5A and B). Moreover, the kappa antagonist
norBNI failed to alter ICSS in rats treated with intraplantar
saline, and it also failed to block formalin-induced
depression of ICSS in rats treated with intraplantar
formalin (Figure 5C-E). Data in Figure 5C-E show results
obtained on Day 8 after intraplantar injection and 22 hr
after norBNI administration. Rats were also tested daily for
another six days (Days 9-14 after intraplantar injection),
and norBNI did not significantly alter either control ICSS
or formalin-depressed ICSS on any day (data not shown).
Discussion
This study compared effects of intraplantar CFA and
formalin on a series of behavioral and physiological
endpoints in rats. There were four main findings.
First, in agreement with previous studies, both CFA
and formalin produced similar degrees of paw swelling and
mechanical hypersensitivity. Second, CFA and formalin
produced different effects on ICSS. Specifically, CFA
produced relatively weak and transient depression of
ICSS, whereas formalin produced a more robust and
sustained depression of ICSS that lasted as long as
14 days. Third, formalin-induced depression of ICSS could
be reversed by morphine doses that had no significant
effect on ICSS in saline-treated rats, suggesting that
formalin effects on ICSS can be interpreted as an example
of pain-related and analgesic-reversible depression of
behavior. Finally, neither behavioral nor central biomarker
data support a role for the endogenous kappa opioid
system in mediation of formalin-induced depression of
ICSS. These results suggest differential efficacy of sustained
pain stimuli to depress brain reward function in rats as
assessed with ICSS.
CFA-and formalin effects on paw width, mechanical
allodynia and body weight
The CFA and formalin effects reported here agree with
previous studies in rats that examined the time course of
paw swelling and/or mechanical sensitivity after intraplantar
CFA [5,31,18] or formalin [15,32,18]. For example, Fu et al.
[15] demonstrated that a 5% formalin injection into the
hindpaw of rats produced both mechanical and thermal
allodynia for up to four weeks following administration.
Similarly, Grace et al. [18] found that bilateral injection
of either CFA or formalin into the hindpaw resulted
in mechanical allodynia that lasted up to seven days.
Transient weight loss in CFA-treated rats, but not
formalin-treated rats, is also consistent with previous
studies. For example, 100 μl CFA administered to the
tail-base in rats produced a magnitude and time course of
weight loss similar to that reported here [33], whereas rats
gained weight normally for six weeks after unilateral
intraplantar injection of 50 μl5 %f o r m a l i n[ 3 4 ] .
Differential effects of CFA and formalin on ICSS
Although CFA and formalin produced similar effects on
mechanical allodynia as a measure of pain-stimulated
behavior, they produced distinct effects on depression of
ICSS as a measure of pain-depressed behavior. The greater
and more sustained efficacy of formalin to depress ICSS
may be related to its induction of necrosis in the paw,
neuropathy of primary afferents, and/or microglial
activation at the level of the spinal cord [16,12,17], and we
are actively investigating the role of these formalin effects
in formalin-induced depression of ICSS. However, regard-
less of mechanism, these results extend the range of pain-
related stimuli that have been found to depress brain
reward function as assessed with ICSS in rats, and further
identify bilateral intraplantar formalin as the stimulus
producing the most sustained depression of ICSS so far
reported. For example, previous studies have shown transi-
ent (1-2 hr) pain-related and analgesic-reversible depression
of ICSS by intraperitoneal injection of dilute acid [25,26],
and ICSS was also depressed for up to three hours by intra-
plantar CFA (present study) and for up to two days by paw
incision [27]. In contrast, effects of bilateral intraplantar
formalin in the present study lasted for at least 14 days.
Moreover, the poor efficacy of unilateral intraplantar
formalin to alter ICSS in this study agrees with the
finding that a unilateral spinal nerve ligation-model of
neuropathy also failed to alter ICSS at any time [27].
Figure 4 Formalin induced-depression of intracranial
self-stimulation (ICSS) is dose and time related. Abscissa: Days
after varying doses of intraplantar formalin or saline administration.
Ordinate: ICSS rate expressed as percent baseline stimulations per
component. Statistical analysis was performed using two-way
Repeated Measures ANOVA followed by the Holm-Sidak post hoc
test (p <0.05). Dollar signs ($) indicate a significant within-group
difference from the pre-injection baseline, and filled points indicate
a significant between-group difference at that time point relative to
saline treatment. All data show mean ± SEM from 6 rats per treatment.
See Additional file 1 for detailed statistical results.
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ICSS also warrant comparison to CFA and formalin
effects on some other metrics of pain-related behavioral
depression and/or negative affective states. For example,
unilateral treatment in rats with intraplantar CFA doses
similar to that used here depressed diurnal exploratory
activity for four weeks [35] and burrowing for 10 days
[36]; however, pain-related changes in facial expression
or place conditioning were apparent for only one day
[37,38], and neither nocturnal locomotor activity nor
wheel running were significantly affected at any time
[35,18]. Bilateral CFA injection, such as that used in the
present study, did depress both nocturnal locomotor
activity (for four weeks) and wheel running (for two days) in
rats, and studies in mice have also reported a requirement
for bilateral CFA treatment to produce transient depression
of wheel running [39]. Taken together, these results indicate
that CFA has different efficacies and time courses to
produce different pain-related behaviors, and ICSS in
rats is relatively resistant to CFA effects.
Fewer studies have examined effects of formalin in
procedures of pain-related behavioral depression and/or
negative affective states. Perhaps of greatest relevance to
the present study, bilateral intraplantar formalin produced
avoidance for six weeks of noxious thermal stimuli in an
operant-escape procedure [34]. Intraplantar formalin has
also been shown to produce pain-related changes in facial
expression and place conditioning [40-42], but these
effects were evaluated only for the first hour after formalin
administration, and more sustained formalin effects on
these procedures have not been examined. Lastly, in
contrast to formalin effects on ICSS, bilateral intraplantar
formalin administration had no effect on wheel running in
rats [18]. This distinction is notable, because the failure of
bilateral intraplantar formalin to alter either body weight
(present study) or wheel running [18] provides evidence
to suggest that ICSS depression by formalin could not be
attributed to general behavioral impairment.
Morphine reversal of formalin-induced depression of ICSS
The failure of morphine to significantly alter ICSS in rats
after intraplantar saline treatment is consistent with
previous studies showing little or no effect of these
morphine doses on ICSS in opioid-naïve rats [25,43,44].
Figure 5 Role of the endogenous kappa opioid system in pain-related depression of ICSS. Panels A and B: Transcript levels of PDYN (A)
or KOR (B) mRNA as measured by qRT-PCR in brain regions implicated in mood disorders (CPu: caudate/putamen, NAc: nucleus acumbens core,
NAcSh: nucleus acumbens shell, PFC: prefrontal cortex, VTA: ventral tegmental area). Abscissae: Brain area evaluated. Ordinates: Transcript levels
expressed as “Fold-Induction” relative to saline controls. “ND” in Panel B signifies “Not Determined” due to low transcript levels below the level of
detection in some rats. Panel C-D: Effects of the kappa antagonist norBNI (32 mg/kg) on ICSS in rats treated with intraplantar saline (C) or formalin
(D). Abscissae show frequency of electrical brain stimulation (Log Hz). Ordinates show ICSS rate expressed as percent maximum control rate
(%MCR). “BL” shows the frequency-rate curve determined on Day 7 after intraplantar saline or formalin and immediately before norBNI treatment.
ICSS was then redetermined 24 hr after norBNI. Summary data are shown in Panel E, where the abscissa shows norBNI dose in mg/kg in rats that
received intraplantar saline (open bars) or formalin (filled bars), and the ordinate shows ICSS rate expressed as total stimulations per component
relative to the pre-formalin baseline. The asterisk (*) indicates a significant between-group difference at a given dose. All data show mean ± SEM
from 6 rats. See Additional file 1 for detailed statistical results.
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formalin-induced depression of ICSS, consistent with
previous studies showing that morphine also blocks
acute depression of ICSS by IP acid [25,19]. Moreover, the
high potency of morphine to block formalin-induced
depression of ICSS (effective at 0.32 mg/kg) is similar to
the high potency of morphine to block acid-induced
depression of ICSS [25]. Reversal of formalin-induced
depression of ICSS by the opioid analgesic morphine
provides one source of evidence to suggest that this
formalin effect may be related to sustained pain.
In the present study, high morphine doses not only
reversed formalin-induced depression of ICSS but also
increased ICSS above original baseline levels. Mechanisms
responsible for this morphine effect are not currently
known; however, the emergence of rate-increasing effects
produced by these morphine doses after formalin
treatment is similar to the emergence or enhancement
of rate-increasing effects produced by regimens of
prior morphine exposure [45]. Formalin treatment has
been reported to promote endogenous opioid release
[46-48], and this raises the possibility that endogenous
opioid release stimulated by formalin treatment had the
effect of sensitizing rats to rate-increasing effects of subse-
quent treatment with the exogenous opioid morphine.
NorBNI failed to reverse formalin-induced depression
of ICSS
Administration of the endogenous kappa agonist dynorphin
or of exogenous kappa agonists like salvinorin A is
sufficient to decrease mesolimbic dopamine release and to
depress ICSS in rodents [49-51,43]. In addition, previous
studies have shown that some non-pain stressors can
increase central biomarkers for kappa opioid function and
produce depression-like behaviors that can be blocked by
kappa antagonists [52,53,29,54]. These findings have
suggested the possibility that activation of endogenous
kappa opioid systems might also mediate pain-related
depression of ICSS. Accordingly, the present study tested
the hypothesis that CFA and/or formalin might activate
endogenous kappa opioid signaling and produce kappa
antagonist-reversible depression of ICSS. However, the
present results do not support this hypothesis for four
reasons. First, neither CFA nor formalin significantly
increased central PDYN or KOR mRNA levels. Second,
although this analysis may have failed to detect small but
real changes in kappa biomarkers (a Type II error), there
was no pattern for either a trend toward increased
biomarker levels or a difference in CFA and formalin
effects on biomarkers consistent with the difference in
their effects on ICSS. Third, CFA- and formalin-induced
changes in PDYN never approached the nearly two-fold
increase in PDYN produced in rats exposed to the stress
of a forced swim test [53]. Finally, the formalin-induced
decrease in ICSS was not blocked by the kappa antagonist
norBNI, suggesting that any modest effects that formalin
might have had on kappa biomarkers were not sufficient
to produce a kappa receptor-mediated decrease in ICSS.
Additional files
Additional file 1: Detailed Statistical Results.
Additional file 2: Figure S1. Shows effects of formalin (filled bars) or
saline (open bars) on ICSS during the first 50 minutes of testing immediately
following intraplantar administration. Abscissa: Time (in 10 minute bins) after
intraplantar formalin or saline administration. Ordinates: ICSS rate expressed
as total stimulations per component relative to baseline. Data were
analyzed by two-way ANOVA followed by the Holm-Sidak post-hoc test
(p<0.05). All points show mean ± SEM from 8 rats. Statistical results are as
follows. Significant main effect of treatment [F(1, 14)=13.141; p=0.003],
significant main effect of time [F(4,56)=13.394; p<0.001], and a significant
interaction of treatment x time [F(4,56)=3.928; p=0.007]. Dollar signs ($)
indicate a significant within-group difference from the respective baseline,
and asterisks (*) indicate a significant between-group difference at a given
time point, as determined by a significant two-way ANOVA followed by the
Holm-Sidak post hoc test (p<0.05).
Additional file 3: Figure S2. Shows effects of complete Freund’s
adjuvant (CFA, filled gray bars in Panel A), formalin (filled bars in Panel B),
or respective controls (open bars in both panels) on ICSS during lever
height challenges. Abscissae show lever heights (low, middle or high) on
days 1, 3 and 7 following treatment. Ordinates show ICSS rate expressed
as total stimulations per component relative to baseline determined at
the low lever height before intraplantar treatment. Data were analyzed
by three-way ANOVA followed by the Holm-Sidak post-hoc test (p< 0.05).
All points show mean ± SEM from 6 rats. Statistical results are as follows.
Panel A. Significant main effect of day [F(2,90)=4.148, p=0.019], significant
main effect of lever height [F(2,90)=9.097, p<0.001], but no main effect of
CFA treatment [F(1,90)=0.121, p=0.729] and no significant interactions of
day X lever height (p=0.785), day X treatment (p=0.417), lever height X
treatment (p=0.696), or day X lever height X treatment (p=0.803). Panel B.
Significant main effect of day [F(2,90)=4.669, p=0.012], significant main
effect of lever height [F(2,90)=27.314, p<0.001], and a significant main
effect of formalin treatment [F(1,90)=78.725, p<0.001], but no interactions
of day X lever height (p=0.108), day X treatment (p=0.154), lever height X
treatment (p=0.794), or day X lever height X treatment (p=0.558). Panels
C-E show the posture of a rat responding at the low, medium and high
lever height, respectively. Increases in lever height required increasingly
erect postures and increased weight bearing on the hind paws.
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